Autoimmune Pancreatitis - Recent Advances

J 2010

Autoimmune Pancreatitis - Recent Advances

NOVOTNÝ, Ivo, Petr DÍTĚ, Jan LATA, Hana NECHUTOVÁ, Bohuslav KIANIČKA et. al.

Basic information

Original name

Autoimmune Pancreatitis - Recent Advances

Authors

NOVOTNÝ, Ivo (203 Czech Republic, belonging to the institution), Petr DÍTĚ (203 Czech Republic, guarantor, belonging to the institution), Jan LATA (203 Czech Republic, belonging to the institution), Hana NECHUTOVÁ (203 Czech Republic, belonging to the institution) and Bohuslav KIANIČKA (203 Czech Republic, belonging to the institution)

Edition

DIGESTIVE DISEASES, Basel, Karger AG, 2010, 0257-2753

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.000

RIV identification code

RIV/00216224:14110/10:00046880

Organization unit

Faculty of Medicine

UT WoS

000281607100006

Keywords in English

Autoimmune pancreatitis. IgG4-related sclerosing disease. Corticosteroid therapy. Granulocyte epithelial lesion

Abstract

V originále

Autoimmune pancreatitis (AIP) is recognized as a distinct clinical entity, identified as a chronic inflammatory process of the pancreas in which the autoimmune mechanism is involved. Clinically and histologically, AIP has two subsets: type 1 lymphoplasmatic sclerosing pancreatitis with abundant infiltration of the pancreas and other affected organs with immunoglobulin G4 positive plasma cells, and type 2 duct centric fibrosis, characterized by granulocyte epithelial lesions in the pancreas without systemic involvement. In the diagnosis of AIP, two diagnostic criterions are used the HISORt criteria and Asian Diagnostic Criteria. Typical signs of AIP are concomitant disorders in other organs (kidney, liver, biliary tract, salivary glands, colon, retroperitoneum, prostate). Novel clinicopathological entity was proposed as an IgG4 related sclerosing disease (IgG4 RSC). Extensive IgG4 positive plasma cells and T lymphocyte infiltration is a common characteristics of this disease. Recently, IgG4 RSC syndrome was extended to a new entity, characterized by IgG4 hypergammaglobulinemia and IgG4-positive plasma cell infiltration, this being considered an expression of a lymphoproliferative disease, IgG4-positive multiorgan lymphoproliferative syndrome. This syndrome includes Mikulicz s disease, mediastinal fibrosis, autoimmune hypophysitis, and inflammatory pseudotumor lung, liver, breast. In the therapy of AIP, steroids constitute first-choice treatment. High response to the corticosteroid therapy is an important diagnostic criterion. In the literature, there are no case-control studies that determine if AIP predisposes to pancreatic cancer. Undoubtedly, AIP is currently a hot topic in pancreatology.

Citovat

NOVOTNÝ, Ivo, Petr DÍTĚ, Jan LATA, Hana NECHUTOVÁ and Bohuslav KIANIČKA. Autoimmune Pancreatitis - Recent Advances. DIGESTIVE DISEASES. Basel: Karger AG, 2010, vol. 28, No 2, p. 334-338. ISSN 0257-2753.

@article{920655,
   author = {Novotný, Ivo and Dítě, Petr and Lata, Jan and Nechutová, Hana and Kianička, Bohuslav},
   article_location = {Basel},
   article_number = {2},
   keywords = {Autoimmune pancreatitis. IgG4-related sclerosing disease. Corticosteroid therapy. Granulocyte epithelial lesion},
   language = {eng},
   issn = {0257-2753},
   journal = {DIGESTIVE DISEASES},
   title = {Autoimmune Pancreatitis - Recent Advances},
   volume = {28},
   year = {2010}
}

TY  - JOUR
ID  - 920655
AU  - Novotný, Ivo - Dítě, Petr - Lata, Jan - Nechutová, Hana - Kianička, Bohuslav
PY  - 2010
TI  - Autoimmune Pancreatitis - Recent Advances
JF  - DIGESTIVE DISEASES
VL  - 28
IS  - 2
SP  - 334-338
EP  - 334-338
PB  - Karger AG
SN  - 02572753
KW  - Autoimmune pancreatitis. IgG4-related sclerosing disease. Corticosteroid therapy. Granulocyte epithelial lesion
N2  - Autoimmune pancreatitis (AIP) is recognized as a distinct clinical entity, identified as a chronic inflammatory process of the pancreas in which the autoimmune mechanism is involved. Clinically and histologically, AIP has two subsets: type 1 lymphoplasmatic sclerosing pancreatitis with abundant infiltration of the pancreas and other affected organs with immunoglobulin G4 positive plasma cells, and type 2 duct centric fibrosis, characterized by granulocyte epithelial lesions in the pancreas without systemic involvement. In the diagnosis of AIP, two diagnostic criterions are used the HISORt criteria and Asian Diagnostic Criteria. Typical signs of AIP are concomitant disorders in other organs (kidney, liver, biliary tract, salivary glands, colon, retroperitoneum, prostate). Novel clinicopathological entity was proposed as an IgG4 related sclerosing disease (IgG4 RSC). Extensive IgG4 positive plasma cells and T lymphocyte infiltration is a common characteristics of this disease. Recently, IgG4 RSC syndrome was extended to a new entity, characterized by IgG4 hypergammaglobulinemia and IgG4-positive plasma cell infiltration, this being considered an expression of a lymphoproliferative disease, IgG4-positive multiorgan lymphoproliferative syndrome. This syndrome includes Mikulicz s disease, mediastinal fibrosis, autoimmune hypophysitis, and inflammatory pseudotumor lung, liver, breast. In the therapy of AIP, steroids constitute first-choice treatment. High response to the corticosteroid therapy is an important diagnostic criterion. In the literature, there are no case-control studies that determine if AIP predisposes to pancreatic cancer. Undoubtedly, AIP is currently a hot topic in pancreatology.
ER  -

NOVOTNÝ, Ivo, Petr DÍTĚ, Jan LATA, Hana NECHUTOVÁ and Bohuslav KIANIČKA. Autoimmune Pancreatitis - Recent Advances. \textit{DIGESTIVE DISEASES}. Basel: Karger AG, 2010, vol.~28, No~2, p.~334-338. ISSN~0257-2753.

Detailed Information on Publication Record